Christopher Freeburn

Christopher Freeburn

InvestorPlace Writer

Christopher T. Freeburn has been a financial writer and editor for more than 10 years. He has worked at industry trade publications like Food Logistics, ChemicalWeek and Institutional Investor. His freelance articles have appeared in a variety of magazines, including Technology Review, Audubon and USA Weekend. He lives in Westchester County, just outside New York City.”

Recent Articles

CLVS: Clovis Oncology Lung Cancer Drug Gets Breakthrough Therapy Designation

By Christopher Freeburn, InvestorPlace Writer

Clovis Oncology says the Food and Drug Administration has granted Breakthrough Therapy status to its new lung cancer drug, sending CLVS shares bouncing.

DKS: Weak Golf & Hunting Sales Whack Dick’s Sporting Goods

By Christopher Freeburn, InvestorPlace Writer

Dick's Sporting Goods reported first-quarter profits and sales that missed estimates and lowered its outlook for the year, sending DKS stock down sharply.

Gold and Silver Report: NEM Stock Sinks as Gold Prices Edge Higher

By Christopher Freeburn, InvestorPlace Writer

Gold prices gained 40 cents in Monday trading, the metal's first gain in three sessions. NEM stock fell harder than other miners, closing down almost 3%.

Monday Apple Rumors: Apple and Samsung in New Patent Settlement Talks

By Christopher Freeburn, InvestorPlace Writer

Apple and Samsung negotiating end to patent litigation; Apple corporate logos up for auction; and former iPhone user sues over missing iMessage texts.

PBI: Why Pitney Bowes Is Trading Higher Today

By Christopher Freeburn, InvestorPlace Writer

A Barron's writer says that Pitney Bowes stock could rise 60% over the next three years, sending PBI shares up sharply on Monday.

Load More